BioLife Solutions (BLFS) stock is soaring 5.43% in pre-market trading on Friday, following a better-than-expected earnings report and an analyst price target upgrade. The medical equipment and supplies company has demonstrated resilience in a challenging market environment, surprising investors with its financial performance.

The company reported a quarterly adjusted loss of 1 cent per share for the quarter ended June 30, significantly outperforming the mean expectation of a 4-cent loss from ten analysts. This result also marks an improvement from the 50-cent loss per share reported in the same quarter last year. Although revenue fell 10.3% to $25.42 million, it still surpassed analysts' expectations of $23.71 million, showcasing the company's ability to exceed market projections despite headwinds.

Adding to the positive sentiment, H.C. Wainwright raised its price target for BioLife Solutions from $30 to $32, reflecting increased confidence in the company's prospects. This upgrade, combined with the strong earnings results, has likely fueled investor optimism. The current Wall Street median 12-month price target stands at $30.50, suggesting a potential upside of about 32.3% from its last closing price. With 10 analysts rating the stock as "strong buy" or "buy," BioLife Solutions appears well-positioned for future growth in the medical equipment and supplies sector.